Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis

Study Overview
=================
Brief Summary
-----------------
Wegener's granulomatosis is a primary systemic vasculitis characterized by granulomatous and necrotizing inflammation predominantly affecting the respiratory tract and the kidneys. Conventional therapy of Wegener's granulomatosis with cyclophosphamide and corticosteroids is limited by incomplete remissions and a high relapse rate. Patients accumulate irreversible damage due to the disease and the consequences of prolonged drug exposure. The efficacy and safety of an alternative immunosuppressive drug, gusperimus, was evaluated in patients with refractory disease. A prospective, international, nulti-centre, single limb, open label study. Entry required active Wegener's granulomatosis with a Birmingham Vasculitis Activity Score (BVAS) >=4 and previous therapy with cyclophosphamide or methotrexate. Immunosuppressive drugs were withdrawn at entry and prednisolone doses adjusted according to clinical status. Gusperimus, 0.5mg/kg/day, was self-administered by subcutaneous injection in six treatment cycles of 21 days with a seven day washout between cycles. Cycles were stopped early for white blood count < 4,000/mm3. The primary endpoint was complete remission (BVAS=0 for at least 2 months) or partial remission (BVAS<50% of entry score). After the sixth cycle azathioprine was commenced and follow-up continued for a further six months.

Official Title
-----------------
Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis

Conditions
-----------------
Wegener's Granulomatosis

Intervention / Treatment
-----------------
* Drug: Gusperimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Documented diagnosis of WG according to American College of Rheumatology (ACR) and Chapel Hill Consensus Conference (CHCC) definition BVAS >= 4 Total disease duration >= 3 months treated with CYC or >= 6 months with MTX Age 18 - 80 WBC >= 4,000/mm3, haemoglobin >= 8g/dl, neutrophils >= 2,500/mm3, platelets >= 100,000/mm3 ALT, bilirubin and alkaline phosphatase levels within 2x the upper limits of normal Documented to be non-pregnant by serum/urine pregnancy test Willing to participate in this study Provide signed informed consent Able and prepared to self-administer the study drug or have a close friend/relative able to do this Exclusion Criteria: Participation in another clinical research study Pregnant or nursing mothers and women of childbearing age not using appropriate contraception Clear evidence of active disease due to bacteria/viral infection Patient has an unacceptable risk for participation in a study of immunosuppressive therapy History of substance abuse or psychotic disorders Previous treatment with Gusperimus

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Gusperimus | Drug: Gusperimus<br>* SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Remission of Vasculitis | The primary efficacy outcome measure was remission of vasculitis. Complete remission was defined as a Birmingham vasculitis activity score (BVAS) of 0 sustained for at least 2 months. Partial remission was defined as a reduction in BVAS of 50% or more, sustained for at least 2 months, when compared with the BVAS at entry. Entry required active Wegener's granulomatosis with a BVAS >= 4. Their disease had to be active, as measured with BVAS in which clinical manifestations caused by active vasculitis are scored on a list of predefined organ-specific items. | At Entry (Day 1 of Cycle 1), Day 22 of cycles 1-6, up to 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of Clinical Response | Time from Complete Remission or Partial Remission to Relapse. | At Entry (Day 1 of Cycle 1), Day 22 of cycles 1-6, up to 24 weeks, End of treatment period, and 3 and 6 months of follow-up period | 
| Haematuria | Assessment of anti-inflammatory activity of gusperimus using surrogate marker: number of hematuria-positive patients. | At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks | 
| Creatinine | Assessment of anti-inflammatory activity of gusperimus using surrogate marker: serum creatinine level | At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks | 
| ANCA | Assessment of anti-neutrophil cytoplasmic antibody (ANCA): Number of ANCA-positive patients was counted. ANCA are highly associatred with active WG, with c-ANCA titres observed in 90% of WG. In addition to their diagnostic value, it has been suggested that ANCA may have a predictive value for relapse in patients with systemic vasculitis. | At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks | 
| CRP | Assessment of anti-inflammatory activity of gusperimus using surrogate marker: serum C-reactive protein level. | At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks | 
| Vasculitis Damage Index (VDI) | Assessment of the degree of irreversible damage due to the vasculitis using VDI scoring system. The VDI comprises 64 items of damage (grouped into 11 organ-based systems). Total VDI score is 0 - 64. The higher scores represent the more severe damage occurred in patients. The VDI score can either increase or remain the same over time. | At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks, 6 months of follow-up period | 
| SF-36 | Assessment of the impact of gusperimus on general health using the Short form-36 (SF-36) questionaire. The SF-36 is a self-report, 36 item survey measuring health-related quality-of-life. Thirty-five items are used to construct 8 scales: (1) physical functioning, (2) role physical, (3) bodily pain, (4) general health, (5) vitality, (6) social function, (7) role emotional, and (8) mental health. Raw scores are calculated as the sum of re-coded scale items and transformed to a 0 to 100 scale. If scores for all 8 scales are available, two summary measures known as component scores are derived: the Physical Health Component Score (PCS) and the Mental Health Component Score (MCS). First each scale standardized to the relevant population. Then PCS and MCS are calculated as the weighted sum of standardized scores. All scales and the component scores are positively scored so that higher scores represent better health-related quality-of-life. | At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Wegener Granulomatosis, Vasculitis, Gusperimus, Immunosuppression